论文部分内容阅读
目的 探讨急性淋巴细胞白血病 (ALL)患者血清碱性成纤维细胞生长因子 (bFGF)水平及其临床意义。方法 应用酶联免疫法(ELISA)检测 26例ALL初发未治患者及 5例复发患者化疗前后血清bFGF的水平,并与正常对照组比较。结果 ALL初治患者血清bF GF水平为 (64. 71±27. 45 )pg/L,复发患者血清bFGF水平为 ( 76. 02±27 07 )pg/L,均明显高于正常人对照组水平 ( 24 06±5. 97 )pg/L,差异有非常显著性意义 (P<0. 001, 0. 05 );化疗后完全缓解 (CR)患者血清bFGF水平 [ (29. 64 ±7. 02 )pg/L]明显下降,与对照组相比无显著性差异 (P>0 05 ),经化疗无效 (NR)患者血清bFGF水平 [ 76. 16±29. 83 )pg/L]与化疗前水平 [ ( 82. 11±32. 64 )pg/L]相比无显著性差异 (P>0. 05 );NR组化疗前血清bFGF水平明显高于CR组化疗前的水平 [ 50. 36±12. 52 )pg/L],P<0. 01。结论 ALL患者存在bFGF的异常高表达,检测血清bFGF对ALL的疗效观察和预后判断有一定临床价值。
Objective To investigate the serum level of basic fibroblast growth factor (bFGF) in patients with acute lymphoblastic leukemia (ALL) and its clinical significance. Methods The serum levels of bFGF in 26 cases of newly diagnosed ALL patients and 5 cases of recurrent patients were detected by enzyme-linked immunosorbent assay (ELISA), and compared with the normal control group. Results The serum level of bFGF in patients with ALL was (64. 71 ± 27.45) pg / L and the level of bFGF in patients with relapsed disease was (76.02 ± 27.07) pg / L, which were significantly higher than that of the control group (24.06 ± 5.97) pg / L, the difference was significant (P <0.001, 0.05); serum bFGF levels in patients with complete remission (CR) after chemotherapy [(29.64 ± 7.22 ) pg / L] significantly decreased compared with that of the control group (P> 0.05). The serum bFGF levels in patients with chemotherapy-ineffective (NR) [76.16 ± 29.83 pg / L] (82.11 ± 32.64) pg / L], there was no significant difference between the two groups (P> 0.05). The level of serum bFGF in NR group before chemotherapy was significantly higher than that in CR group 12. 52) pg / L], P <0.01. Conclusion The abnormal expression of bFGF exists in ALL patients. The detection of serum bFGF has some clinical value in the observation and prognosis of ALL.